Tevogen CEO Affirms Strong Growth, Capital Position, and AI Expansion in Letter to Stockholders
1. Tevogen is expanding into AI for innovative therapies. 2. Secured patents position Tevogen at the forefront of predictive modeling. 3. Company is well-capitalized and pursuing accelerated growth strategies. 4. Insider ownership at 74% reinforces commitment to long-term vision. 5. Partnerships with Microsoft and Databricks enhance target discovery efficiency.